TOKYO (Reuters) -Japanese drugmaker Shionogi said on Wednesday that it will acquire Torii Pharmaceutical, a subsidiary of Japan Tobacco, for more than 150 billion yen ($1.05 billion). Shionogi plans ...

Biopharma’s nonprofit deal and grant activity continues to settle into a post-pandemic rhythm, with both showing a sustained ...

An announcement from Shionogi & Co ( ($JP:4507) ) is now available. Shionogi & Co., Ltd. announced the acceptance of its New Drug Application for ...

Shionogi & Co.’s Covid pill could be approved in China this spring as Beijing races to stock up on therapies developed abroad to fight a growing number of severe infections and deaths in the ...

Shionogi has been awarded $375m by the US Department of Health and Human Services (HHS) to develop a long-acting therapeutic aimed at protecting vulnerable populations from Covid-19. The funding ...

Shionogi & Co. shares fell sharply Thursday morning after a Japanese government panel rejected granting emergency approval for the company’s Covid-19 drug. The company’s shares were recently 8 ...

Shionogi & Co.’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy. The panel ...

Japan's Shionogi Says Phase 3 Study Showed COVID Pill Reduces Transmission TOKYO (Reuters) - Japan's Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for ...

However, this allows Shionogi to be the next great COVID opportunity, offering both significant profit generation for shareholder benefit and undervaluation. So far, Xocova has already allowed for ...

Clinigen has entered a new phase of collaboration with Japanese drugmaker Shionogi (TYO: 4507), signing a licensing agreement ...

Shionogi & Co. Ltd. (4507.TO) Osaka Year Ended March 31 GROUP 2025 2024 Revenue Y438.27 bln Y435.08 bln Operating Profit Y156.60 bln Y153.31 bln Pretax Profit Y200.75 bln Y198.28 bln Net Profit ...

Additional presentations show potent in vitro* activity for cefiderocol against emerging pathogens with limited treatment options, including those that are resistant to newer agents OSAKA, Japan ...